[go: up one dir, main page]

SA520411120B1 - مركبات وسيطة مبتكرة مفيدة لتركيب مشتقات الأمينوبيريميدين، وعملية لتحضير هذه المركبات الوسيطة، وعملية لتحضير مشتقات الأمينوبيريميدين باستخدام هذه المركبات - Google Patents

مركبات وسيطة مبتكرة مفيدة لتركيب مشتقات الأمينوبيريميدين، وعملية لتحضير هذه المركبات الوسيطة، وعملية لتحضير مشتقات الأمينوبيريميدين باستخدام هذه المركبات

Info

Publication number
SA520411120B1
SA520411120B1 SA520411120A SA520411120A SA520411120B1 SA 520411120 B1 SA520411120 B1 SA 520411120B1 SA 520411120 A SA520411120 A SA 520411120A SA 520411120 A SA520411120 A SA 520411120A SA 520411120 B1 SA520411120 B1 SA 520411120B1
Authority
SA
Saudi Arabia
Prior art keywords
preparing
same
aminopyrimidine derivatives
intermediates useful
novel intermediates
Prior art date
Application number
SA520411120A
Other languages
English (en)
Inventor
لي جانغ-أي
كهو جا-هيوك
لي جون-سوب
ليم جونغ-تشول
لي دو-بيونغ
جيون سانغ-سول
آوه سانغ-هو
جو هيون
شين وو-سيوب
Original Assignee
يوهان كوربوريشن
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by يوهان كوربوريشن filed Critical يوهان كوربوريشن
Publication of SA520411120B1 publication Critical patent/SA520411120B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/321,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)

Abstract

يوفر الاختراع الحالي عملية محسّنة لتحضير مشتقات أمينو بيريميدين أو أملاح منه مقبولة صيدلانيًا تتميز بنشاط تثبيطي انتقائي ضد كينازات البروتين، وخاصة ضد كينازات البروتين لمستقبلات عوامل النمو البشروية الطافرة. ويوفر الاختراع الحالي أيضًا مركبات وسيطة جديدة مفيدة للعملية المذكورة ولعمليات من أجل تحضيرها.
SA520411120A 2017-07-28 2020-01-22 مركبات وسيطة مبتكرة مفيدة لتركيب مشتقات الأمينوبيريميدين، وعملية لتحضير هذه المركبات الوسيطة، وعملية لتحضير مشتقات الأمينوبيريميدين باستخدام هذه المركبات SA520411120B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20170096220 2017-07-28

Publications (1)

Publication Number Publication Date
SA520411120B1 true SA520411120B1 (ar) 2022-08-25

Family

ID=65040817

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520411120A SA520411120B1 (ar) 2017-07-28 2020-01-22 مركبات وسيطة مبتكرة مفيدة لتركيب مشتقات الأمينوبيريميدين، وعملية لتحضير هذه المركبات الوسيطة، وعملية لتحضير مشتقات الأمينوبيريميدين باستخدام هذه المركبات

Country Status (29)

Country Link
US (1) US10858353B2 (ar)
EP (1) EP3658553B1 (ar)
JP (1) JP7216704B2 (ar)
KR (1) KR102684954B1 (ar)
CN (1) CN111032650A (ar)
AU (1) AU2018308039B2 (ar)
CA (1) CA3069408A1 (ar)
CO (1) CO2020000595A2 (ar)
CY (1) CY1125473T1 (ar)
DK (1) DK3658553T3 (ar)
EA (1) EA038856B1 (ar)
ES (1) ES2923278T3 (ar)
HR (1) HRP20220848T1 (ar)
HU (1) HUE059501T2 (ar)
IL (1) IL271974B (ar)
LT (1) LT3658553T (ar)
MA (1) MA49703A (ar)
MX (1) MX394027B (ar)
MY (1) MY200829A (ar)
PH (1) PH12020500070A1 (ar)
PL (1) PL3658553T3 (ar)
PT (1) PT3658553T (ar)
RS (1) RS63497B1 (ar)
SA (1) SA520411120B1 (ar)
SG (1) SG11201913520YA (ar)
SI (1) SI3658553T1 (ar)
SM (1) SMT202200291T1 (ar)
UA (1) UA125664C2 (ar)
WO (1) WO2019022486A1 (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3658552T3 (da) 2017-07-28 2023-11-20 Yuhan Corp Fremgangsmåde til fremstilling af n-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamid ved reaktion af den tilsvarende amin med et 3-halogen-propionylchlorid
PH12021552798A1 (en) 2019-05-14 2022-09-19 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599041A (en) * 2009-11-13 2014-05-30 Genosco Kinase inhibitors
CN105461695B (zh) * 2014-09-29 2018-03-27 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
HRP20250213T1 (hr) * 2014-10-13 2025-04-25 Yuhan Corporation Spojevi i pripravci za modulaciju aktivnosti egfr mutantne kinaze
CN104788427B (zh) 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
JP6457697B2 (ja) * 2015-04-29 2019-01-23 カントン チョンション ファーマシューティカル カンパニー,リミティド キナーゼ阻害剤としての縮合環式または三環式アリールピリミジン化合物
WO2017027768A1 (en) * 2015-08-13 2017-02-16 The Broad Institute, Inc. Compositions and methods for treating tuberculosis
PT3658547T (pt) * 2017-07-28 2023-10-20 Yuhan Corp Processo de preparação de n -(5 -(4 -(4 -formil -3- fenil- 1h -pirazol- 1 -il)pirimidin -2- ilamino) -4 -metoxi 2- morfolinofenil) acrilamida

Also Published As

Publication number Publication date
HUE059501T2 (hu) 2022-11-28
PL3658553T3 (pl) 2022-10-10
CN111032650A (zh) 2020-04-17
MY200829A (en) 2024-01-17
KR20190013554A (ko) 2019-02-11
PT3658553T (pt) 2022-09-23
IL271974B (en) 2022-08-01
AU2018308039B2 (en) 2022-04-14
PH12020500070A1 (en) 2020-12-07
RS63497B1 (sr) 2022-09-30
SMT202200291T1 (it) 2022-09-14
WO2019022486A1 (en) 2019-01-31
ES2923278T3 (es) 2022-09-26
MA49703A (fr) 2021-04-21
CA3069408A1 (en) 2019-01-31
EP3658553B1 (en) 2022-06-15
JP2020528437A (ja) 2020-09-24
SI3658553T1 (sl) 2022-10-28
CY1125473T1 (el) 2025-05-09
EA038856B1 (ru) 2021-10-28
LT3658553T (lt) 2022-09-12
SG11201913520YA (en) 2020-02-27
IL271974A (en) 2020-02-27
JP7216704B2 (ja) 2023-02-01
AU2018308039A1 (en) 2020-01-30
DK3658553T3 (da) 2022-07-25
KR102684954B1 (ko) 2024-07-15
EP3658553A4 (en) 2021-04-21
US10858353B2 (en) 2020-12-08
UA125664C2 (uk) 2022-05-11
US20200207750A1 (en) 2020-07-02
HRP20220848T1 (hr) 2022-10-14
EP3658553A1 (en) 2020-06-03
EA202090385A1 (ru) 2020-09-09
MX394027B (es) 2025-03-24
CO2020000595A2 (es) 2020-05-05
BR112020001396A2 (pt) 2020-08-11

Similar Documents

Publication Publication Date Title
SA520411112B1 (ar) عملية محسّنة لتحضير مشتقات أمينو بيريميدين
SA520411120B1 (ar) مركبات وسيطة مبتكرة مفيدة لتركيب مشتقات الأمينوبيريميدين، وعملية لتحضير هذه المركبات الوسيطة، وعملية لتحضير مشتقات الأمينوبيريميدين باستخدام هذه المركبات
PH12020500093A1 (en) Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
ZA202202097B (en) Amino pyrimidine ssao inhibitors
AU2018271990A1 (en) Covalent inhibitors of KRAS
MX393879B (es) Métodos de preparación de niraparib.
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
MX373102B (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
PH12017550004B1 (en) Heterocyclic derivatives and use thereof
MX2020012063A (es) Sales farmaceuticas de derivados de pirimidina y metodo de tratamiento de trastornos.
SG11201906435SA (en) Pyrimidine compound and pharmaceutical use thereof
MX2021007247A (es) Derivados de rapamicina.
AU2018375456A1 (en) Thieno(3,2-d)pyrimidine compound having inhibitory activity for protein kinase
AU2019248350A8 (en) Process for making sarecycline hydrochloride
WO2018193415A9 (en) Process for the preparation of pirlindole enantiomers and its salts